Preoperative FDG PET/CT in breast cancer patients: Where are we going?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 11, 2012, Pages 1667-1669

  Gilardi, Laura ^a   De Cicco, Concetta ^a   Paganelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE;

AXILLARY LYMPH NODE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; EDITORIAL; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE DISSECTION; PREOPERATIVE EVALUATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TREATMENT PLANNING;

BREAST NEOPLASMS, MALE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84868208163     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2245-2     Document Type: Editorial

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Norum J, Andreassen T. Screening for metastatic disease in newly diagnosed breast cancer patients. What is cost-effective? Anticancer Res 2000;20:2193-6.
3. Cermik TF, Mavi A, Basu S, Alavi A. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging 2008;35:475-83.
4. Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;18:3495- 502.
5. Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16.
6. Kang BJ, Lee JH, le Yoo R, Kim SH, Choi JJ, Jeong SH, et al. Clinical significance of incidental finding of focal activity in the breast at 18F-FDG PET/CT. AJR Am J Roentgenol 2011;197:341-7.
7. Berriolo-Riedinger A, Touzery C, Riedinger J-M, Toubeau M, Coudert B, Arnould L, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34:1915-24.
8. Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009;36:1551-7.
9. Sanli Y, Kuyumcu S, Ozkan ZG, Işik G, Karanlik H, Guzelbey B, et al. Increased FDG uptake in breast cancer is associated with prognostic factors. Ann Nucl Med 2012;26:345-50.
10. Kim BS, Sung SH. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med 2012;26:175-83.
11. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/ computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 2008;38:250-8.
12. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [18F]2-deoxy-2-fluoro-D- glucose-positron emission tomography. J Cancer Res Clin Oncol 2004;130:273-8.
13. De Cicco C, Gilardi L, Botteri E, Fracassi SLV, Di Dia GA, Botta F, et al. Is [(18)F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? Breast 2012. doi:10.1016/ j.breast.2012.05.009.
14. Wahl R, Siegel BA, Coleman RE, Gatsonis CG, PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004;22:277-85.
15. Monzawa S,Adachi S, Suzuki K,Hirokaga K, Takao S, Sakuma T, et al. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT. Ann Nucl Med 2009;23:855-61.
16. Veronesi U, De Cicco C, Galimberti E, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007;18:473-8.
17. Vinh-Hung V, Everaert H, Lamote J, Voordeckers M, van Parijs H, Vanhoeij M, et al. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging 2012. doi:10.1007/s00259-012-2181-1.
18. Kumar R, Zhuang H, Schnall M, Conant E, Damia S, Weinstein S, et al. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun 2006;27:231-6.
19. Gerber B, Heintze K, Stubert J, Dieterich M, Hartmann S, Stachs A, et al. Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today? Breast Cancer Res Treat 2011;128:613-24.
20. Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, et al. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med 2012. doi:10.2967/ jnumed.111.098640.
21. Giuliano AE, Hunt KK, Ballman KV, Beitsh PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569-75.
22. Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, et al. Comparison between positron emission tomography using 2-[fluorine-18] fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 2008;19:1249-54.
23. Niikura N, Costelloe CM, Madewell JE, Hayashi N, Yu T-K, Liu J, et al. FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist 2011;16:1111-9.
24. Koolen BB, Vrancken Peeters MJTFD, Aukema TS, Vogel WV, Oldenburg HAS, van der Hage JA, et al. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat 2012;131:117-26.
25. Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, et al. Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008;26:4746-51.
26. Segaert I, Mottaghy F, Ceyssens S, DeWeverW, Stroobants S, Van Ongeval C, et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J 2010;16:617-24.
27. Groheux D, Giacchetti S, Espié M, Vercellino L, Hamy A-S, Delord M, et al. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med 2011;52:1526-34.
28. Bernsdorf M, Berthelsen AK, Wielenga VT, Kroman N, Teilum D, Binderup T, et al. Preoperative PET/CT in early-stage breast cancer. Ann Oncol 2012;23:2277-82. doi:10.1093/annonc/mds002.
29. Aukema TS, Straver ME, Vrancken Peeters MJTFD, Russell NS, Gilhuijs KGA, Vogel WV, et al. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer 2010;46:3205-10.
30. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
31. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.